-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the European Medicines Agency (EMA) announced that the European Union has approved the listing of two new crown monoclonal antibody drugs
Ronapreve is approved for the treatment of adults and adolescent patients (over 12 years old and weighing at least 40 kg) who do not require supplemental oxygen and are at increased risk of disease deterioration.
Ronapreve, jointly developed by Roche and Regeneron Pharmaceuticals, is a combination therapy consisting of two neutralizing antibodies targeting different epitopes of the new coronavirus spike protein
Regkirona's approval is supported by positive data from Phase 3 clinical trials
Neutralizing antibodies, as a treatment method for the new coronavirus, can also provide effective treatment for patients with low immunity
Reference materials:
[1] COVID-19: EMA recommends authorisation of two monoclonal antibody medicines.
[2] BIO COVID-19 Therapeutic Development Tracker.